R&D The Chairman & CEO of SV More speaks about the path that led him to found the company nearly three decades ago, what changes need to be made in the future in order to maintain the current success of the company, and what aspect of his company makes him the…
Generics David Goodman, CEO of Pharmascience, describes the importance of balancing innovation with low cost products in Canada and outlines his company’s strategy for growth domestically and internationally. 2013 marks the thirtieth anniversary of Pharmascience. How does the company’s original business compare with its business today? Pharmascience was first established as…
R&D Patrick Tête, Managaing Director of Servier Philippines, speaks about the differences between running the company in Australia and in the Philippines, that the office and company culture is very similar, however, working in a healthcare system exposed to such severe corruption clearly makes the job more complicated in the Philippines.…
R&D António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the US, as well as the unique long-term strategy of the company and the advantages to being a family-run business. Last…
R&D Ramón Palou de Comasema, Country Director of Amgen Portugal, talks about the struggle to enter the reimbursement process in Portugal, how Amgen Portugal has broken this trend by having three of its products reimbursed in the last four years, and further highlights the affiliate’s successes and future growth outlook. How…
partnering David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic areas. In what way do you think the pharmaceutical industry can act as an engine of economic recovery and development…
R&D Angelini Portugal’s Luigi Cianci offers his critique of the decline of Portugal’s economy and its effects on the industry, talking specifically about the company’s presence in Portugal and its export market—Angelini is one of a few multinationals that produces in conjunction with local facilities. What is your perception of the…
R&D Nelson Ambrogio, managing director of Bayer Portugal, talks about tthe collaboration between the industry and the government, he recent successes of his affiliate, and strategies for continued growth during the toughest years of the crisis in Portgugal. Why did you choose to come to Portugal during such a challenging time…
R&D Servier Portugal’s general manager José Albino Mendes discusses how Portugal’s economic crisis provides real opportunities for growth, the potential for attracting talent in innovative research, and the affiliate’s recently opened international center for research. You have managed Servier Portugal for ten years. From your perspective, could you describe the evolution…
R&D Nuno Brás, General Manager of LEO Farmacêuticos discusses the effect of the crisis on the Portuguese pharmaceutical market, how being a small privately owned company was an advantage during the crisis, and what future growth looks like for the company as well as the industry. You have had the opportunity…
R&D Fermin Rivas Lopez, Country Manager of Celgene Portugal, gives his insight on Portugal’s recent economic problems, the challenges Celgene Portugal faces due to the economic state of the country, and what the strategy is to stay afloat. You joined Celgene Portugal earlier this year; why were you chosen to take…
UAE Amin Al Amiri, Assistant undersecretary for Medical Practice and Licensee of Ministry of Health, UAE, discusses why the UAE, despite turmoil in the rest of the Middle East region, continues to be a destination for the pharmaceutical industry, how MOH plans on supporting standardization across the region, and how recruiting…
See our Cookie Privacy Policy Here
